AbbVie EVP Perry Siatis sells 18,668 shares

AbbVie Inc. executive Perry C. Siatis, EVP, GC and Secretary, reported several stock transactions.

Rhea-AI Filing Summary

AbbVie Inc. executive Perry C. Siatis, EVP, GC and Secretary, reported several stock transactions. On February 27, 2026, he disposed of 14,850 common shares at $232.08 per share to cover tax obligations. On March 2, 2026, he conducted open-market sales totaling 18,668 common shares at weighted average prices between about $233 and $235.36. Following these sales, his directly owned common stock holdings were reported in the filing at reduced levels after each transaction.

Insider Trade Summary

Net Seller: 18,668 shares

Net Sell 4 txns

Insider Siatis Perry C

Role EVP, GC AND SECRETARY

Sold 18,668 shs ($4.38M)

Type	Security	Shares	Price	Value
Sale	Common Stock, $0.01 par value	5,777	$233.51	$1.35M
Sale	Common Stock, $0.01 par value	10,291	$234.66	$2.41M
Sale	Common Stock, $0.01 par value	2,600	$235.26	$612K
Exercise Price or Tax Liability	Common Stock, $0.01 par value	14,850	$232.08	$3.45M

Holdings After Transaction: Common Stock, $0.01 par value — 4,619 shares (Direct)

Footnotes (3)

1. F1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233 to $233.99, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. F2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.14 to $235.12, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. F3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did AbbVie (ABBV) executive Perry C. Siatis report?

Perry C. Siatis reported a tax-related share disposition and open-market sales of AbbVie stock. On February 27, 2026 he disposed of 14,850 shares, and on March 2, 2026 he sold 18,668 shares in multiple open-market transactions at weighted average prices around $233–$235 per share.

How many AbbVie (ABBV) shares did Perry C. Siatis sell in the open market?

He sold a total of 18,668 AbbVie common shares in open-market transactions on March 2, 2026. These sales occurred in three tranches of 5,777, 10,291, and 2,600 shares, at weighted average prices between $233.51 and $235.26 per share, with detailed ranges noted in footnotes.

What was the purpose of Perry C. Siatis’s February 27, 2026 AbbVie (ABBV) share disposition?

The February 27, 2026 transaction was a tax-withholding disposition. Siatis delivered 14,850 AbbVie common shares at $232.08 per share to satisfy exercise price or tax liabilities, as indicated by transaction code F and its description in the reported data.

At what prices did Perry C. Siatis’s AbbVie (ABBV) stock sales occur?

The filing shows weighted average sale prices of $233.51, $234.66, and $235.26 per share. Footnotes explain these represent multiple trades with price ranges: $233–$233.99, $234.14–$235.12, and $235.14–$235.36, with full breakdowns available on request to AbbVie or regulators.

How many AbbVie (ABBV) shares did Perry C. Siatis hold after his reported transactions?

After the tax-withholding disposition on February 27, 2026, his directly owned AbbVie shares were 23,287. Subsequent sales on March 2, 2026 reduced his directly owned holdings to reported levels of 17,510 shares, then 7,219 shares, and finally 4,619 shares following the last sale tranche.

Were Perry C. Siatis’s AbbVie (ABBV) stock transactions direct or indirect holdings?

All reported AbbVie transactions involved directly owned common stock. The records classify each as direct ownership, with ownership code “D” and no nature-of-ownership footnote indicating trusts, partnerships, or entities holding shares on his behalf in these specific transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 06:10 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Siatis Perry C

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GC AND SECRETARY

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	02/27/2026		F		14,850	D	$232.08	23,287	D
Common Stock, $0.01 par value	03/02/2026		S		5,777	D	$233.51(1)	17,510	D
Common Stock, $0.01 par value	03/02/2026		S		10,291	D	$234.66(2)	7,219	D
Common Stock, $0.01 par value	03/02/2026		S		2,600	D	$235.26(3)	4,619	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $233 to $233.99, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $234.14 to $235.12, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $235.14 to $235.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ T.O. Odutayo, Attorney-in-Fact for Perry C. Siatis	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.